Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04096417 |
TitlePemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | 阶段
第二阶段
|
Date Added 2019-09-19 |
地点
Arizona, United States
Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pemigatinib |
标签
MSS/ MMRp
|
| NCT ID NCT04092673 |
TitleeFT226 对部分晚期实体瘤恶性肿瘤受试者的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-17 |
地点
California, United States
Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
eFT226, eFT226 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04085185 |
Title评估 IBI110 对晚期恶性肿瘤患者的安全性、耐受性和初步疗效的研究 | 阶段
第 1 阶段
|
Date Added 2019-09-11 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04062721 |
TitleLocal Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases | 阶段
第 1 阶段
|
Date Added 2019-08-20 |
地点
法国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Chemotherapy, In situ immunotherapy |
标签
MSS/ MMRp
|
| NCT ID NCT04050709 |
TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | 阶段
第 1 阶段
|
Date Added 2019-08-08 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
PD-L1 t-haNK |
标签
MSS/ MMRp
|
| NCT ID NCT04046445 |
Title对 IV 期结直肠癌患者进行 ATP128、VSV-GP128 和 BI 754091 评估的 1b 期研究 | 阶段
第 1 阶段
|
Date Added 2019-08-06 |
地点
Arizona, United States
California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States 比利时 德国 瑞士 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ATP128, BI 754091, VSV-GP128 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04041310 |
TitleNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2019-08-01 |
地点
California, United States
Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States 比利时 加拿大 意大利 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd
|
| NCT ID NCT04017650 |
TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2019-07-12 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT04014530 |
TitlePembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | 阶段
第 1 阶段
|
Date Added 2019-07-10 |
地点
荷兰
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Ataluren + Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT04009681 |
Title评估THOR-707对晚期或转移性实体瘤成人受试者安全性和治疗活性的研究 | 阶段
第 1 阶段
|
Date Added 2019-07-05 |
地点
Arizona, United States
Colorado, United States Florida, United States Tennessee, United States Texas, United States 阿根廷 澳大利亚 智利 新加坡 西班牙 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
anti-EGFR antibody, Checkpoint inhibitor, THOR-707 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
